Gamida Cell

Gamida Cell receives $4.4M grant from the Israeli Government

Thursday, May 26, 2016

Gamida Cell, a provider of cellular and immune therapies for the treatment of cancer and orphan genetic diseases, has been awarded a grant of up to $4.4 million from the Israel Innovation Authority (formerly the Office of the Chief Scientist) of the Israeli Ministry of Economy and Industry. The mission of the Israel Innovation Authority is to encourage innovation and entrepreneurship in various industries, including science and technology, while stimulating economic growth.

[Read More]

Pfizer, Gamida Cell ink investment and option agreement

Wednesday, August 20, 2014

Gamida Cell, an Israel-based provider of stem cell expansion technologies and therapeutic products, has signed an investment and option agreement with Novartis Pharma. Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord, anticipated to be met during 2015.

[Read More]